Zhongguo aizheng zazhi (Jul 2021)

The advances in immunotherapy biomarkers of small cell lung cancer

  • XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia

DOI
https://doi.org/10.19401/j.cnki.1007-3639.2021.07.010
Journal volume & issue
Vol. 31, no. 7
pp. 635 – 639

Abstract

Read online

 There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years, and the prognosis has not improved significantly. With the opening of the immune era, immune checkpoint inhibitors have made breakthroughs in SCLC treatment, but the overall benefit population is limited. How to select patients accurately and how to increase the efficacy of immunotherapy are hot topics in SCLC research. Therefore, this article summarized the current status of SCLC with focus on biomarkers related to SCLC immunotherapy, reviewed the progress in the research of immunotherapy markers in recent years, to provide clues and ideas for future immunotherapeutic strategies.

Keywords